The tariff classification of Brivaracetam Tablets and Eltrombopag Tablets in dosage form, from India
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Ruling text
In your letter dated July 18, 2025, you requested a tariff classification ruling. The first product, Brivaracetam, imported in dosages of 10 mg, 25 mg, 50 mg, 75 mg and 100 mg tablets, is an anticonvulsant drug. It is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. The second product, Eltrombopag, imported in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets, is a thrombopoietin receptor agonist.
It is indicated for treatment of thrombocytopenia (low blood platelet counts) in patients with persistent or chronic immune thrombocytopenic, thrombocytopenia in patients with chronic hepatitis C infection, and patients with severe aplastic anemia.
The applicable subheading for the Brivaracetam Tablets in dosage form will be 3004.90.9236, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Medicaments primarily affecting the central nervous system: Anticonvulsants, hypnotics and sedatives.” The general rate of duty will be free.
The applicable subheading for the Eltrombopag Tablets in dosage form will be 3004.90.9221, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments… consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Cardiovascular medicaments: Other.” The general rate of duty will be free.
Effective April 5, 2025, Executive Orders implemented “Reciprocal Tariffs.” All imported merchandise must be reported with either the Chapter 99 provision under which the reciprocal tariff applies or one of the Chapter 99 provisions covering exceptions to the reciprocal tariffs. At this time, products of India will be subject to an additional ad valorem rate of duty of 25 percent. Your products fall within an excepted subheading.
At the time of entry, you must report the Chapter 99 heading applicable to your product classification, i.e. 9903.01.32, in addition to subheadings 3004.90.9221 and 3004.90.9236, HTSUS, listed above. The tariffs and additional duties cited above are current as of this ruling’s issuance. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided at https://hts.usitc.gov/.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
Brivaracetam may also be subject to the Controlled Substances Act, which is administered by the U.S. Drug Enforcement Administration (DEA), Office of Diversion Control.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N351480).